Diseases & Conditions
Grants & Contracts
News & Events
Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.
The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
In vivo imaging is gaining increasing interest for the characterization of infectious diseases, including the ones caused by high-consequence pathogens.
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
PathogenAR is an Augmented Reality application from the National Institute for Allergy and Infectious Diseases (NIAID). Explore interactive stories about pathogens and pathogenic disease using touch gestures or a Merge Cube Device.
The pathology and histology laboratories at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) work together to conduct comprehensive postmortem examinations on laboratory animals of a variety of species studied as models for high-consequence emerging human viral infections.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
The virology team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has extensive expertise working with a range of high‑consequence viral pathogens.